NCT02998476 2025-08-22A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)Incyte CorporationPhase 2 Completed60 enrolled 15 charts
NCT03039114 2025-08-21Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)Incyte CorporationPhase 1 Completed26 enrolled